

**Client**  
**Gurugram**  
Pathkind Diagnostics Pvt. Ltd.  
Plot No. 55-56, Udhog Vihar Ph-IV, Gurugram - 122015

**Processed By**  
**Pathkind Diagnostics Pvt. Ltd.**  
Plot No. 55-56, Udhog Vihar Ph-IV, Gurugram - 122015

<b>Name</b> : Mr. CL111	<b>Billing Date</b> : 07/07/2023 12:17:43
<b>Age</b> : 35 Yrs	<b>Sample Collected on</b> : 10/07/2023 10:01:31
<b>Sex</b> : Male	<b>Sample Received on</b> : 10/07/2023 11:02:13
<b>P. ID No.</b> : P1000100012593	<b>Report Released on</b> : 10/07/2023 15:37:30
<b>Accession No</b> : 10002304649	<b>Barcode No.</b> : 10002304649
<b>Referring Doctor</b> : Self	<b>Ref no.</b> :
<b>Referred By</b> :	

**Report Status - Final**

Test Name	Result	Biological Ref. Interval	Unit
-----------	--------	--------------------------	------

**BIOCHEMISTRY**

<b># Tacrolimus</b>	10.50	5.00 - 20.00	ug/L
<i>Sample: Whole Blood EDTA</i>			
<i>Method: LCMS</i>			

**Tacrolimus**

LCMS is considered the most sensitive and specific technology for Therapeutic drug monitoring (TDM). It is commonly used to help maintain drug levels within the concentration range in which the drug exerts its clinical effect with minimal adverse reactions. Tacrolimus is a potent immunosuppressant approved for prophylaxis of organ rejection in patients receiving allogeneic liver, kidney and other solid organ transplant patients. Therapeutic ranges are based on specimen collected at trough (ie, immediately before a scheduled dose). Higher results will be obtained when the blood is drawn at other times. Target steady-state trough concentrations vary depending on the type of transplant, concomitant immunosuppression, clinical/institutional protocols, and time post-transplant. Results should be interpreted in conjunction with this clinical information and any physical signs/symptoms of rejection/toxicity.

\*\* End of Report\*\*



**Dr. Daipayan Ghosh**  
Scientist



**Dr. Aarti Khanna Nagpal**  
DNB (Pathology)  
Senior Consultant

